Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Cytomegalovirus (CMV) infection is a common viral infection that can remain latent in the body and cause complications in immunocompromised individuals and newborns. According to Cytogam, global CMV seroprevalence is estimated at 83% in the general population, compared with 75% among adults in the United States. According to cytomegalovirus (CMV) infection epidemiology forecast by Expert Market Research, these figures highlight the disease's widespread prevalence and epidemiological significance.
Base Year
Historical Period
Forecast Period

Read more about this report - Request a Free Sample
Expert Market Research's “Cytomegalovirus (CMV) Infection Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of cytomegalovirus (CMV) infection. It projects the future incidence and prevalence rates of cytomegalovirus (CMV) infection cases across various populations. The study covers age, gender, and type as major determinants of the cytomegalovirus (CMV) infection population. The report highlights patterns in the prevalence of cytomegalovirus (CMV) infection over time and projects future trends based on multiple variables.
The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of cytomegalovirus (CMV) infection in the 8 major markets.
Regions Covered
Cytomegalovirus (CMV) infection is caused by human herpesvirus 5, a member of the Herpesviridae family. The virus spreads through infected bodily fluids, including saliva, urine, blood, and genital secretions, and remains latent in the body after the initial infection. Infection may occur as a primary infection, reactivation of a latent virus, or reinfection with a different strain. Congenital CMV infection occurs when the virus is transmitted from a pregnant woman to her fetus. Although infection is often asymptomatic, viral reactivation can cause serious complications in immunocompromised individuals, including transplant recipients.
|
Parameter |
Insight |
|
Largest Patient Pool |
United States |
|
Fastest Growing Country |
India |
|
High-Risk Population |
Immunocompromised individuals, solid organ transplant recipients, pregnant women, and infants with congenital CMV infection represent important populations for monitoring and intervention. |
|
Key Diagnostic Method |
Polymerase chain reaction testing can detect CMV DNA in appropriate clinical specimens. Serological testing, including immunoglobulin G, immunoglobulin M, and immunoglobulin G avidity testing, supports assessment in relevant settings. |
|
Major Risk Factor |
Immunosuppression increases the risk of clinically significant CMV disease. Exposure to infected bodily fluids and maternal infection or reactivation during pregnancy are also important epidemiological considerations. |
|
Major gap in the market |
Limited awareness, gaps in congenital CMV detection, and the need for improved risk assessment and monitoring among transplant recipients create opportunities for enhanced screening and diagnostic approaches. |
The cytomegalovirus (CMV) Infection epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the cytomegalovirus (CMV) Infection epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for cytomegalovirus (CMV) Infection and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.
|
Epidemiology Segment |
Key Insights |
|
Diagnosed Prevalent Cases of the Disease |
According to Cytogam, global CMV seroprevalence is estimated at 83%, while approximately 75% of adults in the United States are seropositive. CMV infection persists throughout life, and prevalence generally increases with age. |
|
Gender-Specific Cases of the Disease |
According to Karen Fowler et al. (2022), CMV immunoglobulin G seroprevalence among adult men ranged from 39.3% in France to 48.0% in the United States. Among women of reproductive age, seroprevalence varied across regions, reflecting differences in population characteristics and exposure. |
|
Age-Specific Cases of the Disease |
According to the Centers for Disease Control and Prevention, nearly one in three children in the United States is infected with CMV by age five, and more than half of adults have been infected by age 40. Seroprevalence generally increases with age. |
|
Ethnicity-Wise Cases of the Disease |
According to Karen Fowler et al. (2022), CMV seroprevalence is associated with race, ethnicity, socioeconomic status, and educational attainment. Differences in exposure and population characteristics contribute to variations in seroprevalence across demographic groups and geographical regions. |
|
Mortality and Survival Analysis of the Disease |
According to Saravana Priya J. K. et al. (2024), CMV infection among post-renal transplant recipients was associated with graft dysfunction and rejection. Congenital CMV can also result in long-term health complications, including hearing loss, visual impairment, and intellectual disability. |

Read more about this report - Request a Free Sample
The cytomegalovirus (CMV) Infection epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.
|
Country |
Key Insights |
|
United States |
According to Cytogam, approximately 75% of adults in the United States are CMV-seropositive. The Centers for Disease Control and Prevention reports that nearly one in three children is infected by age five, more than half of adults have been infected by age 40, and approximately one in 200 babies is born with congenital CMV infection. |
|
Germany |
According to the German Center for Infection Research (DZIF), approximately 70% of adults in Germany carry CMV. Infection is generally asymptomatic but can become clinically significant in individuals with weakened immune systems, including transplant recipients. Maternal infection during pregnancy is also relevant because congenital transmission can affect fetal and neonatal health. |
|
France |
According to Karen Fowler et al. (2022), CMV immunoglobulin G seroprevalence among adult men in France was 39.3%. The study also reported that CMV seroprevalence among women of reproductive age varied across European populations, ranging from 45.6% to 95.7%. |
|
Italy |
According to Valeria Rubinacci et al. (2022), the incidence of congenital CMV infection in Italy ranges from 0.57% to 1% of live births. Limited awareness among the general population, healthcare professionals, and pregnant women remains a relevant consideration in understanding the burden of congenital infection. |
|
Spain |
According to Maria Angeles Sanchez-Durán et al. (2023), the reported prevalence of congenital CMV infection in Spain is 0.47%, equivalent to approximately one in 200 newborns. Transmission can occur following primary maternal infection or through reactivation or reinfection during pregnancy. |
|
United Kingdom |
According to H. Payne et al. (2025), analysis of more than 3,345 stored newborn dried blood spot samples indicated a potential congenital CMV prevalence of 0.66% in the United Kingdom. The findings highlight the potential burden of congenital infection and the importance of evaluating early screening approaches. |
|
Japan |
According to Masatoki Kaneko et al. (2023), a prospective cohort study involving 1,163 pregnant women reported a congenital CMV prevalence of 0.4% in the study population. Maternal CMV seroprevalence was 82.5%, and congenital infections occurred following both primary and nonprimary maternal infections. |
|
India |
According to Vaishali Rahangdale et al. (2026), approximately 80%–90% of adults in India are seropositive for CMV immunoglobulin G antibodies. The reported prevalence of congenital CMV infection in Indian studies is approximately 1.2% among neonates, while birth prevalence across developing countries, including India, ranges from 0.6% to 6.1% of live births. |
Across the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India, opportunities exist to improve congenital CMV awareness, early detection, and monitoring of high-risk populations. The reported congenital infection burden highlights the importance of evaluating newborn screening strategies and improving recognition of maternal infection. In transplant settings, improved viral monitoring and preventive management may help address complications associated with CMV reactivation. India presents a notable epidemiological opportunity because of its high adult seropositivity and reported congenital infection burden. However, comparative regional market data are needed to establish growth rankings and quantify unmet needs.
Cytomegalovirus (CMV) infection treatment depends on disease severity, immune status, and clinical presentation. Antiviral medications, including ganciclovir and valganciclovir, are commonly used to manage significant CMV disease, particularly in immunocompromised patients and selected infants with symptomatic congenital infection. Foscarnet and cidofovir may be considered in certain cases of antiviral resistance or intolerance. Letermovir is used for prophylaxis in selected transplant recipients. Monitoring viral load, assessing treatment response, and implementing appropriate preventive strategies are important components of antiviral therapy and CMV management.
Hepatitis D Epidemiology Forecast
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Report Features |
Details |
|
Base Year |
2025 |
|
Historical Period |
2019-2025 |
|
Forecast Period |
2026-2035 |
|
Epidemiology Statistics Provided |
|
|
Segmentation Provided |
|
|
Geographies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.